Fisher & Paykel Healthcare Corporation Limited Analysis

Overview

Fisher & Paykel Healthcare is a global leader in medical devices and systems for use in respiratory care and acute care, and in the treatment of obstructive sleep apnea. The company has a consistent growth strategy to provide an expanding range of innovative medical devices which can help to improve care and outcomes for patients in an increasing range of applications.

Its products are sold to hospitals and healthcare facilities around the world through direct sales offices operations and a network of distributors that sell to hospitals, homecare providers and other manufacturers of medical devices.

Formerly Fisher & Paykel Industries, Fisher & Paykel Healthcare arose from the separation of the major trading businesses of Fisher & Paykel Industries into Appliances and Healthcare in November 2001. The company's securities are listed in both New Zealand and Australia.

Performance

The following information was extracted from Fisher & Paykel Healthcare Corporation Limited's half year results, released 26 November 2025:

Fisher & Paykel Healthcare delivers strong growth for the first half; net profit up 39%

Auckland, New Zealand, 26 November 2025 – Fisher & Paykel Healthcare Corporation Limited (NZX:FPH, ASX:FPH) has announced its results for the first half of the 2026 financial year, which ended 30 September 2025.

Total operating revenue was $1.09 billion, an increase of 14% over the first half of the prior financial year, or 12% in constant currency. Net profit after tax was $213.0 million, an increase of 39% over the first half of the prior financial year, or 28% in constant currency.

“Our people have continued to work closely with clinicians, progress work on new products and deliver a range of efficiency improvements across the business,” said Managing Director and Chief Executive Officer Lewis Gradon.

“This is a strong result against the backdrop of robust growth in the first half of last year. We saw broad-based strength across the Hospital consumables portfolio during a period of lower seasonal respiratory hospitalisations, and in Homecare, our latest range of masks for treating obstructive sleep apnea has performed well,” he said.

For the Hospital product group, which includes humidification products used in respiratory, acute and surgical care, first-half revenue was $692.2 million, a 17% increase over the same period last year, or 15% in constant currency. Sales of hardware grew 21% in constant currency, and Hospital new applications consumables revenue increased 16% in constant currency.

For the Homecare product group, which includes products used in the treatment of obstructive sleep apnea (OSA) and respiratory support in the home, first-half revenue was a $395.9 million, an increase of 10% on the first half of last year, or 8% in constant currency.